Author:
Cristina Cardia Maria,Francesca Palmas Maria,Casula Luca,Pisanu Augusta,Marceddu Salvatore,Valenti Donatella,Sinico Chiara,Pini Elena,Scerba Michael T.,Tweedie David,Greig Nigel H.,Rosa Carta Anna,Lai Francesco
Funder
Fondazione di Sardegna
National Institutes of Health
National Institute on Aging
Università degli Studi di Cagliari
Reference35 articles.
1. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability;Amidon;Pharm. Res.,1995
2. The Bidirectional Relationship of Depression and Inflammation: Double Trouble;Beurel;Neuron,2020
3. Bristol Myers Squibb, 2020. U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Pomalyst® (pomalidomide) for AIDS-Related and HIV-Negative Kaposi Sarcoma.
4. Neuroprotection by the Immunomodulatory Drug Pomalidomide in the Drosophila LRRK2WD40 Genetic Model of Parkinson’s Disease;Casu;Front. Aging Neurosci.,2020
5. Chanan-Khan, A.A., Swaika, A., Paulus, A., Kumar, S.K., Mikhael, J.R., Rajkumar, S.V, Dispenzieri, A., Lacy, M.Q., 2013. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J. 3, e143. doi: https://doi.org/10.1038/bcj.2013.38.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献